Since the first HIV products became available nearly three decades ago, we have worked to expand access to our medicines, build healthcare infrastructure, and address health and development challenges around the world.
Approximately 36.7 MILLIONpeople were living with HIV at the end of 2016
Approximately 1.8 MILLIONpeople became newly infected with HIV in 2016
It is estimated that currently only 70% of people with HIV knowtheir status
In the mid-1980s, MSD began its clinical HIV research in response to what the company perceived as a potential epidemic – our scientists were among the first to discover and develop medicines for the treatment of HIV. Today, a future where HIV/AIDS can be a manageable illness is closer, in part, because of MSD’s response to the crisis.LEARN MORE
We continue to explore ways to enhance access to our HIV medicines, particularly in the developing world, and through partnerships that seek to strengthen health systems to better deliver prevention and treatment services. Clearly, the need is too great for any one stakeholder to address, requiring coordinated efforts among many. We are committed to working with governments, donors, innovative and generic manufacturers, multilateral organizations and civil society to address the full range of factors affecting access.LEARN MORE